Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews

INTRODUCTION: Diroximel fumarate (DRF) is an oral fumarate for relapsing multiple sclerosis (MS). Clinical and real-world studies of DRF have demonstrated improved gastrointestinal (GI) tolerability and low (< 1%) GI-related treatment discontinuation versus dimethyl fumarate (DMF) and high rates...

Descripción completa

Detalles Bibliográficos
Autores principales: Gudesblatt, Mark, Roman, Cortnee, Singer, Barry A., Schmidt, Hollie, Thomas, Jessica, Shankar, Sai L., Lyons, Jennifer, Kapadia, Shivani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098785/
https://www.ncbi.nlm.nih.gov/pubmed/35556227
http://dx.doi.org/10.1007/s12325-022-02164-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098785/
https://www.ncbi.nlm.nih.gov/pubmed/35556227
http://dx.doi.org/10.1007/s12325-022-02164-8

Ejemplares similares